Treatment with P2X3 modulators
P2X3 antagonists effectively treat endometriosis by modulating neuronal activity, addressing the recurrence and side effects of current treatments, providing substantial pain relief and symptom reduction.
Patent Information
- Application Number
- JP2021549617
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-25
- Filing Date
- 2020-02-24
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-02-24
AI Technical Summary
Current treatments for endometriosis often result in recurrence of pain and side effects, highlighting the need for more effective therapeutic agents.
The use of P2X3 modulating agents, specifically P2X3 antagonists, to treat endometriosis by administering a therapeutically effective amount to mammals, including humans, to alleviate pain and symptoms associated with the condition.
P2X3 antagonists provide significant relief from endometriosis-related pain and symptoms by modulating neuronal excitability, reducing hyperexcitability of sensory nerves, and decreasing pain sensitivity.
Smart Images

Figure 0007578602000042 
Figure 0007578602000043 
Figure 0007578602000001
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 810,163, filed February 25, 2019, which is incorporated by reference in its entirety. [Background technology]
[0002] Endometriosis is a common gynecological disease in which endometrial tissue grows outside the uterus, often in the pelvic region. Endometriosis lacks effective treatment options because current therapies often result in recurrence of endometriosis pain and side effects. Therefore, new therapeutic agents are needed to treat endometriosis. Summary of the Invention [Problem to be solved by the invention]
[0003] The present disclosure provides, for example, the method of treating endometriosis in mammals with P2X3 modulators.The present disclosure also provides the use of P2X3 modulators as medicaments and / or in the manufacture of medicaments for treating endometriosis in mammals, for example humans.In some embodiments, P2X3 modulators are P2X3 antagonists.
[0004] In one aspect, the method of treating endometriosis, endometriosis-associated pain and endometriosis-associated symptoms in a mammal in need of treatment, comprising administering a therapeutically effective amount of a P2X3 antagonist to the mammal.In some embodiments, the method of treating endometriosis in a mammal in need of treatment, comprising administering a therapeutically effective amount of a P2X3 antagonist to the mammal.In some embodiments, the method of treating endometriosis in a mammal in need of treatment, comprising administering a therapeutically effective amount of a P2X3 antagonist to the mammal.In some embodiments, the method of treating endometriosis in a mammal in need of treatment, comprising administering a therapeutically effective amount of a P2X3 antagonist to the mammal.In some embodiments, the method of treating endometriosis in a mammal in need of treatment, comprising administering a therapeutically effective amount of a P2X3 antagonist to the mammal. In some embodiments, a method of treating a symptom associated with endometriosis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a P2X3 antagonist, wherein the symptom is selected from dysmenorrhea, dyspareunia, dysuria and dysfecation.
[0005] In some embodiments, there is provided a method of treating endometriosis, pain associated with endometriosis, and symptoms associated with endometriosis in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a P2X3 antagonist, wherein the P2X3 antagonist has formula (I): [ka] (In the formula, R 1 is selected from the group consisting of cyano, halogen, methyl and ethyl; R 2 is selected from the group consisting of hydrogen, halogen, methyl and ethyl; R 3 is selected from the group consisting of halogen, methyl and ethyl; R 4is selected from the group consisting of hydrogen, halogen, methyl, ethyl and methoxy; R 5 and R 6 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, and hydroxy-C1-C6 alkyl; or R 5 and R 6 taken together with the nitrogen to which they are both attached form a 5- or 6-membered heterocycloalkyl, where the heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, and C1-C4 alkyl; R 7 and R 8 is independently selected from the group consisting of hydrogen and C1-C4 alkyl; R 9 is selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl-C3-C6 cycloalkyl, halo-C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy and C1-C6 alkoxy-C1-C6 alkyl; X is selected from the group consisting of a bond, CH2 and O. or a pharma- ceutically acceptable salt thereof.
[0006] In some embodiments, R 1 is methyl. In some embodiments, R 2 is hydrogen. In some embodiments, R 3 is fluoro. In some embodiments, X is O. In some embodiments, the compound of formula (I) has the structure [ka] corresponds to R 4 is selected from the group consisting of halogen, methyl and ethyl. 5 is hydrogen. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, R6 is methyl. In some embodiments, R 7 is hydrogen. In some embodiments, R 8 is hydrogen. In some embodiments, R 9 is C1-C6 alkoxy. In some embodiments, R 9 is methoxy. In some embodiments, the compound of formula (I) has the structure [ka] In some embodiments, the compound of formula (I) corresponds to the structure:
[0007] [ka] [ka] [ka] [ka] is equivalent to.
[0008] In some embodiments, the compound of formula (I) has the structure: [ka] is equivalent to.
[0009] In some embodiments, the compound of formula (I) has the structure: [ka] is equivalent to.
[0010] In some embodiments, the compound of formula (I) has the structure: [ka] is equivalent to.
[0011] In some embodiments, the compound of formula (I) has the structure: [ka] is equivalent to.
[0012] In some embodiments, the P2X3 antagonist has the structure: [ka] is equivalent to.
[0013] In some embodiments, the P2X3 antagonist has the structure: [ka] is equivalent to.
[0014] In some embodiments, the P2X3 antagonist has the structure: [ka] is equivalent to.
[0015] In some embodiments, the method of treating endometriosis, endometriosis-associated pain and endometriosis-associated symptoms in a mammal in need of such treatment comprises administering a therapeutically effective amount of a P2X3 antagonist to the mammal, wherein the mammal is a human. In some embodiments, the method of treating endometriosis in a mammal in need of such treatment comprises administering a therapeutically effective amount of a P2X3 antagonist of formula (I) as described herein to the mammal. In some embodiments, the method of treating endometriosis-associated pain in a mammal in need of such treatment comprises administering a therapeutically effective amount of a P2X3 antagonist of formula (I) as described herein to the mammal. In some embodiments, the method of treating endometriosis-associated symptoms in a mammal in need of such treatment comprises administering a therapeutically effective amount of a P2X3 antagonist of formula (I) as described herein to the mammal. In some embodiments, the method of treating endometriosis-associated symptoms in a mammal in need of such treatment comprises administering a therapeutically effective amount of a P2X3 antagonist of formula (I) as described herein to the mammal. In some embodiments, the method of treating symptoms associated with endometriosis in a mammal in need of such treatment comprises administering a therapeutically effective amount of a P2X3 antagonist of formula (I) as described herein to the mammal, wherein the symptoms associated with endometriosis are selected from dysmenorrhea, dyspareunia, difficulty in urination and difficulty in defecation.In some embodiments, the method of treating endometriosis, pain associated with endometriosis and symptoms associated with endometriosis in a mammal in need of such treatment with a P2X3 antagonist of formula (I) as described herein, wherein the P2X3 antagonist is formulated for administration to the mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, topical administration or eye drop administration.In some embodiments, the method of treating endometriosis, endometriosis-related pain and endometriosis-related symptoms in a mammal in need of treatment with P2X3 antagonist of formula (I) as described herein, wherein P2X3 antagonist is formulated in the form of tablet, pill, capsule, liquid, suspension, gel, dispersion, solution, emulsion, ointment or lotion.In some embodiments, the method of treating endometriosis, endometriosis-related pain and endometriosis-related symptoms in a mammal in need of treatment, comprising administering a therapeutically effective amount of P2X3 antagonist of formula (I) as described herein to the mammal, and further comprising administering a second therapeutic agent. In some embodiments, a method for treating endometriosis, endometriosis associated pain and endometriosis associated symptoms in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a P2X3 antagonist of formula (I) as described herein, and further comprising administration of a second therapeutic agent selected from hormonal contraceptives, nonsteroidal anti-inflammatory drugs (NSAIDs), prostaglandin E synthase (PTGES) inhibitors, interleukin-1 receptor associated kinase 4 (IRAK4) inhibitors, prostanoid EP4 receptor antagonists, aldo-keto reductase 1C3 (AKR1C3) inhibitors and prolactin receptor (PRLR) antagonists.
[0016] INCORPORATION BY REFERENCE All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]
[0017] [Figure 1A] FIG. 1 shows von Frey filaments generated in syngeneic C57BL / 6 mice treated with Compound 1 (30 mg / kg, intraperitoneally). [Figure 1B] FIG. 2 shows von Frey filaments generated in syngeneic C57BL / 6 mice treated with meloxicam (5 mg / kg, intraperitoneally). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] The pain associated with endometriosis is due to functional endometriotic lesions embedded with nerve fibers outside the uterine cavity. Afferent sensory fibers and proinflammatory mediators are correlated with the pain associated with endometriosis. In particular, women with endometriosis have high levels of proinflammatory cytokines, such as high levels of interleukin (IL)-1β, IL-6, prostaglandins (PG), tumor necrosis factor (TNF)-α, and nerve growth factor (NGF), in the peritoneal fluid and endometriotic lesions. Inflammatory mediators in the endometriotic peritoneal inflammatory microenvironment activate non-nociceptors in afferent neurons by stimulating sensory nerve fibers (including C- or Aδ-fibers) innervated within the endometriotic lesion, resulting in sensitization of sensory nerves and ultimately triggering a pain signal cascade. In some cases, anti-inflammatory drugs provide analgesia. However, these agents often provide minimal relief of pain symptoms and can result in relapse and significant side effects (Ding et al., PloS one, 2017, 12(9), pp. 1-17; Yuan et al., Int. J. Nanomed., 2017, pp. 8171-8183).
[0019] Afferent neurons found in endometriotic lesions outside the uterine cavity consist of C- or Aδ-fibers of the dorsal root ganglion, which synapse with the spinal cord. C- and Aδ-fiber terminals express receptors that respond to proinflammatory mediators to initiate action potentials that are transmitted to the CNS. The key transducers of this signaling pathway expressed by these nerves are the P2X3 cation channels. Notably, P2X3 channels are co-expressed on the cell membrane of small and medium-diameter sensory nerves, which are important pain transducers of noxious stimuli. In addition, P2X3 expression in endometriotic endometrium and endometriotic lesions is significantly higher than in normal endometrial tissue, and both are positively associated with endometriosis-associated pain (Han et al., Nat. Neurosci., 2013, pp. 174-182; Vilotti et al., PloS one, 2013, 8(11):e81138; Ding et al., PloS one, 2017, 12(9), pp. 1-17).
[0020] P2X3 channels are neuronal excitability regulators activated by the localized release of the neurotransmitter and proinflammatory cytokine ATP. ATP is well established as an important chemical messenger released in excess by neural and non-neuronal cell types in numerous pathological conditions (Burnstock, Front. Pharmacol., 2017, 661; Burnstock, Biochem. Pharmacol., 2017, doi:10.1016 / j.bcp.2017.07.016). Thus, under pathophysiological conditions, increased release of ATP modified by inflammatory mediators may lead to activation of P2X3, leading to increased excitability of afferent neurons located in the endometrium outside the uterine cavity, and increased sensitivity to pain associated with endometriosis. Overall, P2X3 channels acting through pathological ATP release may be a potentially suitable target for modifying afferent neuronal sensing coupled with endometriosis-associated pain. Blocking them offers an approach to alleviate pain resulting from endometriosis and endometriosis-like conditions (Yuan et al., Int. J. Nanomed., 2017, pp. 8171-8183).
[0021] definition As used herein, and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to "an agent" includes a plurality of such agents, and a reference to "the cell" includes a reference to one or more cells (or cells) and equivalents thereof. When ranges are used herein for physical properties, such as molecular weight, or for chemical properties, such as chemical formulas, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about," when referring to a number or numerical range, means that the number or numerical range referred to is an approximation within experimental variability (or within experimental statistical error), such that the number or numerical range varies between 1% and 15% of the stated number or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that in other specific embodiments, for example, in the embodiment of any composition, such as a material, composition, method or process described herein, it may "consist of" or "consist essentially of" the recited features.
[0022] As used in this specification and the appended claims, unless specified to the contrary, the following terms have the meanings indicated below.
[0023] As used herein, C1-C x is C1~C2, C1~C3...C1~C x Includes C1~C x refers to the number of carbon atoms (excluding optional substituents) that make up the molecule it names.
[0024] "Amino" refers to the group -NH2.
[0025] "Cyano" refers to the radical -CN.
[0026] "Nitro" refers to the -NO2 group.
[0027] "Oxa" refers to the group --O--.
[0028] "Oxo" refers to the group ═O.
[0029] "Thioxo" refers to the group ═S.
[0030] "Imino" refers to the group ═NH.
[0031] "Oximo" refers to the group =N-OH.
[0032] "Alkyl" or "alkylene" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, and having from 1 to 15 carbon atoms (e.g., C1-C 15 In certain embodiments, alkyl comprises 1 to 13 carbon atoms (e.g., C1 to C 13 In certain embodiments, the alkyl comprises 1-8 carbon atoms (e.g., C1-C8 alkyl). In other embodiments, the alkyl comprises 1-6 carbon atoms (e.g., C1-C6 alkyl). In other embodiments, the alkyl comprises 1-5 carbon atoms (e.g., C1-C5 alkyl). In other embodiments, the alkyl comprises 1-4 carbon atoms (e.g., C1-C4 alkyl). In other embodiments, the alkyl comprises 1-3 carbon atoms (e.g., C1-C3 alkyl). In other embodiments, the alkyl comprises 1-2 carbon atoms (e.g., C1-C2 alkyl). In other embodiments, the alkyl comprises 1 carbon atom (e.g., C1 alkyl). In other embodiments, the alkyl comprises 5-15 carbon atoms (e.g., C5-C6 alkyl). 15In other embodiments, the alkyl group includes 5 to 8 carbon atoms (e.g., C5 to C8 alkyl). In other embodiments, the alkyl group includes 2 to 5 carbon atoms (e.g., C2 to C5 alkyl). In other embodiments, the alkyl group includes 3 to 5 carbon atoms (e.g., C3 to C5 alkyl). In other embodiments, the alkyl group includes methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), and 1-pentyl (n-pentyl). The alkyl is attached to the remainder of the molecule by a single bond. Unless otherwise specified specifically in the specification, the alkyl group includes any of the following: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR, -O- ... a , -SR a , -OC(O)R a , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, -N(R a )C(O)OR f , -OC(O)-NR a R f , -N(R a )C(O)R f , -N(R a )S(O) t R f (wherein t is 1 or 2), -S(O) t OR a (wherein t is 1 or 2), -S(O) t R f (wherein t is 1 or 2) and -S(O) t N(R a )2, where t is 1 or 2, and wherein each R a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; each R fis independently alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl.
[0033] "Alkoxy" refers to a group attached through an oxygen atom of the formula -O-alkyl, where alkyl is an alkyl chain as defined above.
[0034] "Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from 2 to 12 carbon atoms. In certain embodiments, an alkenyl contains from 2 to 8 carbon atoms. In other embodiments, an alkenyl contains from 2 to 4 carbon atoms. An alkenyl is attached to the remainder of the molecule by a single bond, and is, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unless otherwise specified specifically in the specification, an alkenyl group can be any of the following: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR, -O- ... a , -SR a , -OC(O)-R f , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, -N(R a )C(O)OR f , -OC(O)-NR a R f , -N(R a )C(O)R f , -N(R a )S(O) t R f (wherein t is 1 or 2), -S(O) t OR a (wherein t is 1 or 2), -S(O) t R f (wherein t is 1 or 2) and -S(O) t N(R a)2, where t is 1 or 2, and wherein each R a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; each R f is independently alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl.
[0035] "Alkynyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, and having from 2 to 12 carbon atoms. In certain embodiments, alkynyls contain from 2 to 8 carbon atoms. In other embodiments, alkynyls contain from 2 to 4 carbon atoms. Alkynyls are attached to the remainder of the molecule by a single bond and are, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless otherwise specified specifically in the specification, alkynyl groups include halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR, -O- ... a , -SR a , -OC(O)R a , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, -N(R a )C(O)OR f , -OC(O)-NR a R f , -N(R a )C(O)R f , -N(R a )S(O) t R f (wherein t is 1 or 2), -S(O) t OR a (wherein t is 1 or 2), -S(O) t R f (wherein t is 1 or 2) and -S(O) t N(R a)2, where t is 1 or 2, and wherein each R a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; each R f is independently alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl.
[0036] "Aryl" refers to a group derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon from 6 to 18 carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic delocalized (4n+2) π-electron system according to the Hückel theory. Ring systems from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indene, indene, tetralin, and naphthalene. Unless otherwise specified in this specification, the term "aryl" or the prefix "ar-" (as in "aralkyl") refers to any of the following: alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2, -Rb -OR c -C(O)N(R a )2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t OR a (wherein t is 1 or 2), -R b -S(O) t R a (wherein t is 1 or 2), -R b -S(O) t R a (wherein t is 1 or 2) and -R b -S(O) t N(R a t is 1 or 2; a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; each R b are independently a direct bond or a linear or branched alkylene or alkenylene chain; R c is a straight or branched alkylene or alkenylene chain.
[0037] "Aryloxy" refers to a group attached through an oxygen atom of the formula -O-aryl, where aryl is defined above.
[0038] "Aralkyl" is a group of the formula -R c -aryl group, where R cis an alkylene chain as defined above, e.g., methylene, ethylene, etc. The alkylene chain part of the aralkyl group is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl group is optionally substituted as described above for an aryl group.
[0039] "Aralkyloxy" refers to a group attached through an oxygen atom of the formula -O-aralkyl, where aralkyl is defined above.
[0040] "Aralkenyl" is a group of the formula -R d -aryl group, where R d is an alkenylene chain as defined above. The aryl part of the aralkenyl group is optionally substituted as described above for an aryl group. The alkenylene chain part of the aralkenyl group is optionally substituted as described above for an alkenylene group.
[0041] "Aralkynyl" refers to a group of the formula -R e -aryl group, where R e is an alkynylene chain as defined above. The aryl part of the aralkynyl group is optionally substituted as described above for an aryl group. The alkynylene chain part of the aralkynyl group is optionally substituted as described above for an alkynylene chain.
[0042] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, having from 3 to 15 carbon atoms. In certain embodiments, cycloalkyls contain from 3 to 10 carbon atoms. In other embodiments, cycloalkyls contain from 5 to 7 carbon atoms. Cycloalkyls are attached to the remainder of the molecule by a single bond. Cycloalkyls are saturated (i.e., contain only a single C-C bond) or partially unsaturated (i.e., contain one or more double or triple bonds). Examples of monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In certain embodiments, cycloalkyls contain from 3 to 8 carbon atoms (e.g., C3-C8 cycloalkyl). In other embodiments, cycloalkyls contain from 3 to 7 carbon atoms (e.g., C3-C7 cycloalkyl). In other embodiments, cycloalkyls contain from 3 to 6 carbon atoms (e.g., C3-C6 cycloalkyl). In other embodiments, cycloalkyl contains 3-5 carbon atoms (e.g., C3-C5 cycloalkyl). In other embodiments, cycloalkyl contains 3-4 carbon atoms (e.g., C3-C4 cycloalkyl). Partially unsaturated cycloalkyls are also referred to as "cycloalkenyls." Examples of monocyclic cycloalkenyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Examples of polycyclic cycloalkyl groups include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise specified in the specification, the term "cycloalkyl" includes any of the following: alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -OC(O)-R a , -R b-OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2, -R b -OR c -C(O)N(R a )2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (wherein t is 1 or 2), -R b -S(O) t OR a (wherein t is 1 or 2), -R b -S(O) t R a (wherein t is 1 or 2) and -R b -S(O) t N(R a )2, where t is 1 or 2, a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; each R b are independently a direct bond or a linear or branched alkylene or alkenylene chain; R c is a straight or branched alkylene or alkenylene chain.
[0043] "Halo" or "halogen" refers to a bromo, chloro, fluoro or iodo substituent.
[0044] "Haloalkyl" refers to an alkyl group, as defined above, that is substituted by one or more halo groups, as defined above.
[0045] "Fluoroalkyl" refers to an alkyl group, as defined above, that is substituted with one or more fluoro groups, such as trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. The alkyl portion of the fluoroalkyl group is optionally substituted as defined above for an alkyl group.
[0046] "Haloalkoxy" refers to an alkoxy group, as defined above, that is substituted by one or more halo groups, as defined above.
[0047] "Heterocycloalkyl" refers to a stable 3- to 18-membered non-aromatic ring group containing 2 to 12 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. Unless otherwise specifically stated herein, a heterocycloalkyl group is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, including fused, spiro, or bridged ring systems. The heteroatoms in a heterocycloalkyl group are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl group is partially or fully saturated. In some embodiments, a heterocycloalkyl is attached to the remainder of the molecule through any atom of the ring. Examples of such heterocycloalkyls include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise in this specification, the term "heterocycloalkyl" includes any of the following: alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b-C(O)OR a , -R b -C(O)N(R a )2, -R b -OR c -C(O)N(R a )2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (wherein t is 1 or 2), -R b -S(O) t OR a (wherein t is 1 or 2), -R b -S(O) t R a (wherein t is 1 or 2) and -R b -S(O) t N(R a t is 1 or 2; a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, b are independently a direct bond or a linear or branched alkylene or alkenylene chain; R c is a straight or branched alkylene or alkenylene chain.
[0048] "Heteroaryl" refers to a group derived from a 5- to 18-membered aromatic ring group containing 1 to 17 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, a heteroaryl group refers to a monocyclic, bicyclic, tricyclic or tetracyclic ring system, in which at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic delocalized (4n+2) π-electron system according to the Hückel theory. Heteroaryl includes fused or bridged ring systems. The heteroatoms in a heteroaryl group are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. Heteroaryl is attached to the remainder of the molecule through any atom of the ring. Unless otherwise specified specifically in this specification, the term "heteroaryl" includes any of the following: alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2, -R b -OR c -C(O)NR a 2, -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (wherein t is 1 or 2), -Rb -S(O) t OR a (wherein t is 1 or 2), -R b -S(O) t R a (wherein t is 1 or 2) and -R b -S(O) t N(R a t is 1 or 2; a is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl; each R b are independently a direct bond or a linear or branched alkylene or alkenylene chain; R c is a straight or branched alkylene or alkenylene chain.
[0049] "N-heteroaryl" refers to a heteroaryl group, as defined above, containing at least one nitrogen, where the point of attachment of the heteroaryl group to the remainder of the molecule is through a nitrogen atom in the heteroaryl group. The N-heteroaryl group is optionally substituted as described above for heteroaryl groups.
[0050] "C-heteroaryl" refers to a heteroaryl group as defined above, where the point of attachment of the heteroaryl group to the remainder of the molecule is through a carbon atom in the heteroaryl group. The C-heteroaryl group is optionally substituted as defined above for heteroaryl groups.
[0051] "Heteroaryloxy" refers to a group attached through an oxygen atom of the formula -O-heteroaryl, where heteroaryl is defined above.
[0052] "Heteroarylalkyl" refers to a group of the formula -R c-heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkyl group is optionally substituted as defined above for an alkylene chain. The heteroaryl portion of the heteroarylalkyl group is optionally substituted as defined above for a heteroaryl group.
[0053] "Heteroarylalkoxy" refers to a group of the formula -OR c - refers to a group attached through an oxygen atom of a heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkoxy group is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkoxy group is optionally substituted as defined above for a heteroaryl group.
[0054] In some embodiments, the compounds disclosed herein contain one or more asymmetric centers, thus giving rise to enantiomers, diastereomers, and other stereoisomeric forms defined in terms of absolute stereochemistry, such as (R)- or (S)-. Unless otherwise specified, all stereoisomeric forms of the compounds disclosed herein are intended to be contemplated by the present disclosure. When the compounds described herein contain an alkene double bond, unless otherwise specified, the present disclosure is intended to include both E and Z geometric isomers (e.g., cis and trans). Similarly, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included. The term "geometric isomer" refers to the E or Z geometric isomers (e.g., cis or trans) of the alkene double bond. The term "positional isomer" refers to structural isomers around a central ring, such as ortho-, meta-, and para-isomers around a benzene ring.
[0055] "Tautomer" refers to a molecule capable of proton shift from one atom of the molecule to another atom of the same molecule. In certain embodiments, the compounds present herein exist as tautomers. In situations where tautomerism is possible, a chemical equilibrium of tautomers will exist. The exact ratio of tautomers depends on several factors, including the physical situation, temperature, solvent, and pH. Some examples of tautomer equilibrium include: [ka] Examples include:
[0056] "Optionally" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes examples when the event or circumstance occurs and examples when it does not occur. For example, "optionally substituted aryl" means that the aryl group may be substituted or unsubstituted, and that the description includes both substituted aryl groups and aryl groups that have no substituents.
[0057] "Prodrugs" include compounds that are metabolized into pharmacologically active drugs after administration (RB Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action," Academic Press, Chapter 8). Prodrugs can be used to improve how a compound is absorbed, distributed, metabolized, or excreted.
[0058] "Pharmaceutically acceptable salt" includes both acid and base addition salts. Any one of the pharmaceutically acceptable salts of the compounds described herein is intended to include any and all pharmaceutically suitable salt forms. The preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0059] "Pharmaceutically acceptable acid addition salts" refers to salts which are not biologically or otherwise undesirable and which retain the biological effectiveness and properties of the free acid, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, etc. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanediol acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc., including, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. Thus, exemplary salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, hydrochloride, bromide, iodate, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Also contemplated are the salts of amino acids such as arginate, gluconate and galacturonate (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt.
[0060] "Pharmaceutically acceptable base addition salt" refers to a salt that retains the biological effectiveness and properties of the free acid, which is not biologically or otherwise undesirable. These salts are prepared from the addition of an inorganic or organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals, such as alkali metals and alkaline earth metals, or amines, such as organic amines. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, salts of substituted amines such as naturally occurring substituted amines, salts of cyclic amines and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., supra.
[0061] The term "mammal" refers to humans, non-human primates, dogs, cats, cows, sheep, pigs, mice, or other veterinary or laboratory mammals. Those skilled in the art will recognize that a therapy that reduces the severity of pathology in one species of mammal will predict the effectiveness of the therapy in another species of mammal.
[0062] As used herein, "treatment" or "treat" or "alleviate" or "ameliorate" are used interchangeably herein. These terms refer to an approach to obtain beneficial or desired results, including but not limited to therapeutic benefit and / or preventive benefit. "Therapeutic benefit" refers to eradication or amelioration of the underlying disease being treated. Moreover, therapeutic benefit is achieved with eradication or amelioration of one or more of the physiological symptoms associated with the underlying disease, such that improvement is observed in the patient, even if the patient is still afflicted by the underlying disease. For preventive benefit, the composition is administered to a patient at risk of developing a particular disease, or to a patient who reports one or more of the physiological symptoms of the disease, even if the disease has not been diagnosed.
[0063] method In some embodiments, a method for treating endometriosis, pain associated with endometriosis and symptoms associated with endometriosis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a P2X3 antagonist. In some embodiments, a method for treating endometriosis, pain associated with endometriosis and symptoms associated with endometriosis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a P2X3 antagonist, wherein the P2X3 antagonist has the structure: [ka] (In the formula, R 1 is selected from the group consisting of cyano, halogen, methyl and ethyl; R 2 is selected from the group consisting of hydrogen, halogen, methyl and ethyl; R 3 is selected from the group consisting of halogen, methyl and ethyl; R 4 is selected from the group consisting of hydrogen, halogen, methyl, ethyl and methoxy; R 5 and R 6 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, and hydroxyC1-C6 alkyl; or R 5 and R 6 taken together with the nitrogen to which they are both attached form a 5- or 6-membered heterocycloalkyl, where the heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, and C1-C4 alkyl; R 7 and R 8 is independently selected from the group consisting of hydrogen and C1-C4 alkyl; R 9 is selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl-C3-C6 cycloalkyl, halo-C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy and C1-C6 alkoxy-C1-C6 alkyl; X is selected from the group consisting of a bond, CH2 and O. or a pharma- ceutically acceptable salt thereof.
[0064] In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I) where X is a bond, or a pharma- ceutically acceptable salt thereof. In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I) where X is CH2, or a pharma- ceutically acceptable salt thereof. In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I) where X is O, or a pharma- ceutically acceptable salt thereof.
[0065] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 1 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R1 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 1 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 1 is ethyl), or a pharma- ceutically acceptable salt thereof.
[0066] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 2 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 2 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 2 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 2 is ethyl), or a pharma- ceutically acceptable salt thereof.
[0067] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 3 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 3 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 3 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 3 is ethyl), or a pharma- ceutically acceptable salt thereof.
[0068] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 4 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 4 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 4 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 4 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 4 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 4 is methoxy), or a pharma- ceutically acceptable salt thereof.
[0069] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 5 and R 6 are independently selected from the group consisting of hydrogen and C1-C6 alkyl, or a pharma- ceutically acceptable salt thereof. In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), 5 and R 6 and each are hydrogen, or a pharma- ceutically acceptable salt thereof. In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), 5 and R 6 and R are each C1-C6 alkyl, or a pharma- ceutically acceptable salt thereof. In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), 5 is hydrogen, and R6 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where R 5 is hydrogen, and R 6 is methyl), or a pharma- ceutically acceptable salt thereof.
[0070] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 7 and R 8 is independently selected from the group consisting of hydrogen and methyl, or a pharma- ceutically acceptable salt thereof. In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), 7 and R 8 and each is hydrogen, or a pharma- ceutically acceptable salt thereof. In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), 7 is hydrogen, and R 8 is methyl), or a pharma- ceutically acceptable salt thereof.
[0071] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 9 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), wherein R is selected from the group consisting of C1-C6 alkyl and C1-C6 alkoxy, or a pharma- ceutically acceptable salt thereof. 9 In some embodiments, the P2X3 antagonist is a compound of formula (I), where R is C1-C6 alkyl, or a pharma- ceutically acceptable salt thereof. 9 In some embodiments, the P2X3 antagonist is a compound of formula (I), wherein R is methyl, or a pharma- ceutically acceptable salt thereof. 9 In some embodiments, the P2X3 antagonist is a compound of formula (I), wherein R is ethyl, or a pharma- ceutically acceptable salt thereof. 9In some embodiments, the P2X3 antagonist is a compound of formula (I), where R is C1-C6 alkoxy, or a pharma- ceutically acceptable salt thereof. 9 is methoxy), or a pharma- ceutically acceptable salt thereof.
[0072] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of halogen, methyl and ethyl. In some embodiments of the methods described herein, the P2X3 antagonist is [ka] or a pharma- ceutically acceptable salt thereof.
[0073] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 1 is methyl, R 2 is hydrogen, and R 3 is a halogen, and R 4 is a halogen, and R 5 is hydrogen, and R 6 is C1-C6 alkyl, R 7 is hydrogen, and R 8 is hydrogen, and R 9 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where X is O and R 1 is methyl, R 2 is hydrogen, and R 3 is fluoro and R 4 is fluoro and R 5 is hydrogen, and R 6 is methyl, R 7 is hydrogen, and R8 is hydrogen, and R 9 is methyl), or a pharma- ceutically acceptable salt thereof.
[0074] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 1 is methyl, R 2 is hydrogen, and R 3 is a halogen, and R 4 is a halogen, and R 5 is hydrogen, and R 6 is C1-C6 alkyl, R 7 is hydrogen, and R 8 is hydrogen, and R 9 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where X is O and R 1 is methyl, R 2 is hydrogen, and R 3 is fluoro and R 4 is fluoro and R 5 is hydrogen, and R 6 is methyl, R 7 is hydrogen, and R 8 is hydrogen, and R 9 is methoxy), or a pharma- ceutically acceptable salt thereof.
[0075] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 1 is methyl, R 2 is hydrogen, and R 3 is methyl, R 4 is hydrogen, and R 5 is hydrogen, and R 6 is C1-C6 alkyl, R 7 is hydrogen, and R 8 is hydrogen, and R 9In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where X is O and R 1 is methyl, R 2 is hydrogen, and R 3 is methyl, R 4 is hydrogen, and R 5 is hydrogen, and R 6 is methyl, R 7 is hydrogen, and R 8 is hydrogen, and R 9 is methyl), or a pharma- ceutically acceptable salt thereof.
[0076] In some embodiments of the methods described herein, the P2X3 antagonist is represented by formula (I), 1 is methyl, R 2 is hydrogen, and R 3 is methyl, R 4 is hydrogen, and R 5 is hydrogen, and R 6 is C1-C6 alkyl, R 7 is hydrogen, and R 8 is hydrogen, and R 9 In some embodiments of the methods described herein, the P2X3 antagonist is a compound of formula (I), where X is O and R 1 is methyl, R 2 is hydrogen, and R 3 is methyl, R 4 is hydrogen, and R 5 is hydrogen, and R 6 is methyl, R 7 is hydrogen, and R 8 is hydrogen, and R 9 is methoxy), or a pharma- ceutically acceptable salt thereof.
[0077] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt thereof.
[0078] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] or a pharma- ceutically acceptable salt thereof.
[0079] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] or a pharma- ceutically acceptable salt thereof.
[0080] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] or a pharma- ceutically acceptable salt thereof.
[0081] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] or a pharma- ceutically acceptable salt thereof.
[0082] In some embodiments of the methods described herein, the P2X3 antagonist is [ka] This corresponds to the structure:
[0083] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] is equivalent to.
[0084] In some embodiments of the methods described herein, the P2X3 antagonist has the structure: [ka] is equivalent to.
[0085] In some embodiments of the methods described herein, the method is a method of treating endometriosis. In some embodiments of the methods described herein, the method is a method of treating pain associated with endometriosis. In some embodiments of the methods described herein, the method is a method of treating a symptom associated with endometriosis. In some embodiments of the methods described herein, the method is a method of treating a symptom associated with endometriosis selected from dysmenorrhea, dyspareunia, dysuria, and dysfecation. In some embodiments of the methods described herein, the method is a method of treating dysmenorrhea. In some embodiments of the methods described herein, the method is a method of treating dyspareunia. In some embodiments of the methods described herein, the method is a method of treating dysferic syndrome ...
[0086] In some embodiments of the methods described herein, endometriosis, endometriosis associated pain, and endometriosis associated symptoms are acute conditions. In some embodiments of the methods described herein, endometriosis, endometriosis associated pain, and endometriosis associated symptoms are chronic conditions.
[0087] In certain embodiments, the disclosed compounds utilized by one or more of the foregoing methods are one of the genus, subgenus, or specific compounds described herein, such as compounds of formula (I) described herein.
[0088] Preparation of compounds The compounds used in the methods described herein are made according to the procedures disclosed in U.S. Pat. No. 9,598,409, which is incorporated herein by reference in its entirety, or by known organic synthesis techniques starting from commercially available chemicals and / or from compounds described in the chemical literature. Commercially available chemicals include Acros Organics (Geel, Belgium), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Ark Pharm, Inc. (Libertyville, IL), Avocado Research (Lancashire, UK), BDH Inc. (Toronto, Canada), Bionet (Cornwall, UK), Chemservice Inc. (West Chester, PA), Combi-blocks (San Diego, CA), Crescent Chemical Co. (Hauppauge, NY), eMolecules (San Diego, CA), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, UK), Lancaster Synthesis (Windham, NH), Matrix Scientific (Columbia, SC), Maybridge Chemical Co. Ltd. (Cornwall, UK), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Ryan Scientific, Inc.(Mount Pleasant, SC), Spectrum Chemicals (Gardena, CA), Sandia Meditech (Shanghai, China), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and WuXi (Shanghai, China).
[0089] Suitable reference books and treatises detailing the synthesis of reactants useful in the preparation of the compounds described herein, or providing references to articles describing the preparation, include, for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S.R. Sandler et al., "Organic Functional Group Preparations", 2nd ed., Academic Press, New York, 1983; H.O. House, "Modern Synthetic Reactions", 2nd ed., W.A. Benjamin, Inc. Menlo Park, Calif. 1972; T.L. Gilchrist, "Heterocyclic Chemistry", 2nd ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th ed., Wiley Interscience, New York, 1992. Further suitable reference books and treatises detailing the synthesis of reactants useful in the preparation of the compounds described herein, or providing references to articles describing the preparation, include, for example, Fuhrhop, J. and Penzlin G., Organic Synthesis: Concepts, Methods, Starting Materials, 2nd Revised and Expanded Edition (1994) John Wiley & Sons, ISBN: 3-527-29074-5; Hoffman, RV, Organic Chemistry, An Intermediate Text (1996) Oxford University Press, ISBN: 0-19-509618-5; Larock, RC, Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J."Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th ed. (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. "Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, TWG "Organic Chemistry" 7th ed. (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, JC, "Intermediate Organic "Chemistry" 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999) John Wiley & Sons, ISBN: 3-527-29645-X, 8 volumes; "Organic Reactions" (pp. 1942-2000) John Wiley & Sons, 55+ volumes; and "Chemistry of Functional Groups" John Wiley & Sons, 73 volumes.
[0090] Specific and similar reactants are also identified through the index of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, available at most public and university libraries, as well as through an online database (for further details, The American Chemical Society, Washington, DC, can be contacted). Chemicals that are known but not commercially available in catalogs are sometimes prepared by custom chemical synthesis companies, where many of the standard chemical supply companies (such as those listed above) offer custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is PH Stahl & CG Wermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.
[0091] Further forms of the compounds disclosed herein Isomers Further, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds provided herein include all cis, trans, syn, anti, entgegen (E) and zusammen (Z) isomers, and corresponding mixtures thereof. In some circumstances, the compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. In some circumstances, the compounds described herein have one or more chiral centers, and each center exists in the R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, and corresponding mixtures thereof. In further embodiments of the compounds and methods provided herein, mixtures, combinations, or interconverts of enantiomers and / or diastereoisomers obtained from a single preparation step are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a set of diastereoisomeric compounds and separating the diastereomers to recover the optically pure enantiomers. In some embodiments, dissociable complexes (e.g., crystalline diastereomeric salts) are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and are separated by taking advantage of these differences. In some embodiments, the diastereomers are separated by chiral chromatography or, preferably, by separation / resolution techniques based on differences in solubility. In some embodiments, the optically pure enantiomers are then recovered together with the resolving agent by any practical means that would not result in racemization.
[0092] labeled compound In some embodiments, the compounds described herein are present in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds. In some embodiments, the compounds disclosed herein include methods of treating disease by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are identical to those cited herein, except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, e.g., 2 H, 3 H, 13 C. 14 C. 15 N, 16 O. 17 O. 31 P, 32 P, 35 S, 18 F and 36 The compounds described herein, as well as pharma- ceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, that contain the aforementioned isotopes and / or other isotopes of other atoms, are within the scope of the present invention. 3 H and 14 Certain isotopically labeled compounds, those that incorporate a radioactive isotope such as C, are useful in drug and / or substrate tissue distribution assays. Tritium-labeled, i.e. 3 H, and carbon-14, i.e. 14 C isotopes are particularly preferred due to their ease of preparation and detectability. Additionally, deuterium, i.e. 2Substitution with heavy isotopes such as H offers certain therapeutic advantages resulting from greater metabolic stability, such as increased in vitro half-life or reduced dosage requirements. In some embodiments, isotopically labeled compounds, pharma- ceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof are prepared by any suitable method.
[0093] In some embodiments, the compounds described herein are labeled by other means, including but not limited to the use of chromophoric or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
[0094] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
[0095] In some embodiments, the compounds described herein have acidic or basic groups and thus react with any of a number of inorganic or organic bases, as well as inorganic and organic acids, to form pharma- ceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting the purified compound in its free form with a suitable acid or base and isolating the salt so formed.
[0096] Prodrug In some embodiments, the compounds described herein are formulated as agents that are converted in vivo into active forms to alter the biodistribution or pharmacokinetics of certain agents. For example, a carboxylic acid group can be esterified with a methyl or ethyl group to produce an ester. When the ester is administered to a subject, the ester is enzymatically or non-enzymatically, reductively or oxidatively or hydrolytically cleaved to reveal an anionic group. The anionic group can be esterified with a moiety (e.g., an acyloxymethyl ester) that is cleaved to reveal an intermediate agent and subsequently decomposes to provide an active agent. The prodrug moiety can be metabolized in vivo to a carboxylic acid by esterases or other mechanisms. Alternatively, other functional groups can be modified into prodrug forms. For example, an amine group can be converted to a carbamate or amide that can be cleaved in vivo.
[0097] solvate In some embodiments, the compounds described herein exist as solvates. The invention provides methods of treating diseases by administering such solvates. The invention further provides methods of treating diseases by administering such solvates as pharmaceutical compositions.
[0098] Solvates contain either stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments are formed during the crystallization process with pharma- ceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed during the process described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from aqueous / organic solvent mixtures using organic solvents, including but not limited to dioxane, tetrahydrofuran, or methanol. In addition, the compounds provided herein exist in unsolvated or solvated forms. In general, for the purposes of the compounds and methods provided herein, solvated forms are considered equivalent to unsolvated forms.
[0099] Pharmaceutical Compositions In certain embodiments, the compounds described herein are administered as pure chemicals. In other embodiments, the compounds described herein are combined with a pharma- ceutically suitable or acceptable carrier (also referred to herein as pharma- ceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) that is selected based on the chosen route of administration and standard pharmaceutical practice, e.g., as described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st ed. Mack Pub. Co., Easton, PA (2005)).
[0100] Thus, provided herein are pharmaceutical compositions comprising at least one compound described herein, or a pharma- ceutically acceptable salt, together with one or more pharma- ceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., subject) of the composition.
[0101] One embodiment provides a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (I), or a pharma- ceutically acceptable salt thereof.
[0102] Another embodiment provides a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (I), or a pharma- ceutically acceptable salt thereof.
[0103] In certain embodiments, the compounds described herein are substantially pure in that they contain less than about 5%, or less than about 1%, or less than about 0.1%, of other small organic molecules, such as contaminating intermediates or by-products created during one or more of the steps of a synthetic method.
[0104] These formulations include those suitable for oral, topical, buccal, parenteral (eg, subcutaneous, intramuscular, intradermal or intravenous) or aerosol administration.
[0105] Exemplary pharmaceutical compositions are used in the form of pharmaceutical preparations in solid, semi-solid or liquid form, containing one or more of the disclosed compounds as active ingredients in a mixture with an organic or inorganic carrier or excipient suitable for, for example, topical, enteral or parenteral administration. In some embodiments, the active ingredient is combined with a conventional, non-toxic, pharma- ceutically acceptable carrier for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active compound of interest is included in the pharmaceutical composition in an amount sufficient to produce the desired effect on the disease process or condition.
[0106] In some embodiments, the compound of formula (I) described herein is administered to a subject in a biologically compatible form suitable for topical administration to treat or prevent skin diseases, disorders or conditions.By "biologically compatible form suitable for topical administration" is meant a form of the compound of formula (I) that is administered in which the therapeutic effect of the inhibitor exceeds any toxic effects.The administration of the compound of formula (I) described herein can be in any pharmacological form that contains a therapeutically effective amount of the compound of formula (I) alone or in combination with a pharmaceutically acceptable carrier.
[0107] The topical administration of the compound of formula (I) can be presented in the form of aerosol, semi-solid pharmaceutical composition, powder or solution. By the term "semi-solid pharmaceutical composition" is meant ointment, cream, salve, jelly or other pharmaceutical composition of substantially similar consistency suitable for application to the skin. Examples of semi-solid compositions are given in Chapter 17 of The Theory and Practice of Industrial Pharmacy, Lachman, Lieberman and Kanig, published by Lea and Febiger (1970), and in Remington's Pharmaceutical Sciences, 15th Edition (1975), published by Mack Publishing Company.
[0108] Dermal or skin patches are another method of transdermal delivery of the therapeutic or pharmaceutical compositions described herein. Patches can be provided with an absorption enhancer, such as DMSO, to improve the absorption of the compound. Patches can include those that control the rate of drug delivery to the skin. Patches can provide a variety of dosing systems, including reservoir systems or integrated systems, respectively. Reservoir designs can have, for example, four layers: an adhesive layer that directly contacts the skin, a control membrane that controls the diffusion of the drug molecules, a reservoir of drug molecules, and a water-resistant backing. Such designs deliver a uniform amount of drug over a specific period of time, and the rate of delivery must be below the saturation limit of different types of skin. Integrated designs, for example, typically have only three layers: an adhesive layer, a polymer matrix containing the compound, and a water-resistant backing. This design brings a saturating amount of drug to the skin. Thereby, delivery is controlled by the skin. As the amount of drug decreases in the patch below the saturation level, the delivery rate decreases.
[0109] In one embodiment, the topical composition may take the form of a hydrogel based on polyacrylic acid or polyacrylamide, for example as an ointment with polyethylene glycol (PEG) as a carrier, such as the standard ointment DAB8 (50% PEG300, 50% PEG1500); or as a water-in-oil or oil-in-water based emulsion, in particular a microemulsion, optionally with added liposomes. Suitable penetration enhancers (entrainers) include sulfoxide derivatives such as dimethyl sulfoxide (DMSO) or decyl methyl sulfoxide (decyl-MSO) and transcutol (diethylene glycol monoethyl ether) or cyclodextrins; and pyrrolidones such as 2-pyrrolidone, N-methyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, or biodegradable N-(2-hydroxyethyl)-2-pyrrolidone and their fatty acid esters; urea derivatives such as dodecyl urea, 1,3-didodecyl urea, and 1,3-diphenyl urea; terpenes such as D-limonene, menthone, α-terpineol, carbol, limonene oxide or 1,8-cineol.
[0110] Ointments, pastes, creams and gels can also contain excipients such as starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid and talc, or mixtures thereof. Powders and sprays can also contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. A solution of nanocrystalline antimicrobial metals can be converted into an aerosol or spray by any of the known means commonly used to make aerosol pharmaceuticals. In general, such methods include pressurizing, or providing a means to pressurize a container of the solution, usually with an inert carrier gas, and forcing the pressurized gas through a small orifice. Sprays can additionally contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.
[0111] In some embodiments for the preparation of solid compositions such as tablets, the main active ingredient is mixed with conventional tableting ingredients such as pharmaceutical carriers, e.g., corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents such as water, to form solid preformulation compositions containing a homogenous mixture of the disclosed compounds, or non-toxic pharma-ceutically acceptable salts thereof. When these preformulation compositions are referred to as homogenous, it is meant that the active ingredient is evenly dispersed throughout the composition such that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.
[0112] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the subject compositions may contain sodium citrate or dicalcium phosphate, and / or (1) fillers or extenders, such as starch, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as carboxymethylcellulose, hypromellose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerin; (4) disintegrants, such as crospovidone, croscamellose sodium, sodium starch glycolate, agar, The composition is mixed with one or more pharma- ceutically acceptable carriers such as any of the following: calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarders, such as paraffin; (6) absorption enhancers, such as quaternary ammonium compounds; (7) wetting agents, such as docusate sodium, cetyl alcohol, and glyceryl monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) colorants. In the case of capsules, tablets, and pills, in some embodiments, the composition includes a buffering agent. In some embodiments, solid compositions of a similar type are also utilized as fillers in soft-filled or hard-filled gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols, and the like.
[0113] In some embodiments, tablets are made by compression or molding, optionally with one or more accessory ingredients. In some embodiments, compressed tablets are prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents or dispersants. In some embodiments, molded tablets are made by molding a mixture of the subject composition moistened with an inert liquid diluent in a suitable machine. In some embodiments, tablets and other solid dosage forms such as dragees, capsules, pills and granules are scored or prepared with coatings and shells, such as enteric coatings and other coatings.
[0114] Compositions for inhalation and insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders.Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to the subject composition, in some embodiments, liquid dosage forms contain inert diluents, such as water or other solvents, solubilizing and suspending agents, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (specifically cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerin, tetrahydrofuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, cyclodextrin, and mixtures thereof.
[0115] In some embodiments, suspensions contain, in addition to the subject composition, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0116] In some embodiments, powders and sprays contain, in addition to the subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powder, and mixtures of these substances. In some embodiments, sprays further contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.
[0117] Alternatively, the compositions and compounds disclosed herein are administered by aerosol. This is accomplished by preparing aqueous aerosols, liposomal formulations, or solid particles containing the compounds. In some embodiments, non-aqueous (e.g., fluorocarbon propellant) suspensions are used. In some embodiments, ultrasonic nebulizers are used because they minimize the exposure of the agent to shear, which leads to the degradation of the compounds contained in the composition of interest. Usually, aqueous aerosols are made by formulating an aqueous solution or suspension of the composition of interest together with conventional pharma- ceutically acceptable carriers and stabilizers. Carriers and stabilizers vary with the requirements of a particular composition of interest, but typically include non-ionic surfactants (Tween, Pluronics, or polyethylene glycol), innocuous proteins such as serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols are generally prepared from isotonic solutions.
[0118] Pharmaceutical compositions suitable for parenteral administration include the subject composition in combination with one or more pharma- ceutically acceptable sterile, isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders, to be reconstituted immediately before use into a sterile injectable solution or dispersion, which in some embodiments contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the intended recipient's blood or suspending agents or thickening agents.
[0119] Suitable examples of aqueous and non-aqueous carriers used in pharmaceutical compositions include water, ethanol, polyol (e.g., glycerin, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, injectable organic esters such as ethyl oleate and cyclodextrin.Proper fluidity is maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.
[0120] The dosage of a composition comprising at least one compound described herein will vary depending on the condition of the patient (eg, human), ie, the stage of the disease, general health, age, and other factors.
[0121] The pharmaceutical composition is administered in a manner appropriate for the disease to be treated (or prevented). The appropriate dose and the suitable duration and frequency of administration will be determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. In general, the appropriate dose and treatment regimen provides the composition in an amount sufficient to provide therapeutic and / or prophylactic benefits (e.g., improved clinical outcome, such as more frequent complete or partial relief, or longer disease-free and / or overall survival, or reduced severity of symptoms). The optimal dose is generally determined using experimental models and / or clinical trials. In some embodiments, the optimal dose depends on the patient's body mass, weight, or blood volume.
[0122] Oral doses typically range from about 1.0 mg to about 1000 mg, one to four or more times per day.
[0123] Combination Medicine Also contemplated herein is combination therapy, for example, co-administration of the disclosed compounds with additional active agents as part of a particular treatment regimen that is intended to produce beneficial effects from the co-action of these therapeutic agents. The beneficial effects of combination include, but are not limited to, pharmacokinetic or pharmacodynamic co-actions that result from the combination of therapeutic agents. The administration of these therapeutic agents in combination is typically carried out over a defined period of time (usually weeks, months or years, depending on the combination selected). It is intended that combination therapy includes the administration of multiple therapeutic agents in a sequential manner, i.e., each therapeutic agent is administered at a different time, and the administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
[0124] Substantially simultaneous administration can be achieved, for example, by administering to the subject a single formulation or composition (e.g., tablet or capsule) with a fixed ratio of each therapeutic agent, or multiple, single formulations (e.g., capsules) for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be accomplished by any suitable route, including, but not limited to, oral, intravenous, intramuscular, and direct absorption through mucosal tissue. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the selected combination can be administered by intravenous injection, while the other therapeutic agents of the combination can be administered orally. Alternatively, for example, all therapeutic agents can be administered orally, or all therapeutic agents can be administered by intravenous injection.
[0125] In some embodiments, the method for treating endometriosis, endometriosis-related pain and endometriosis-related symptoms in a mammal in need of treatment comprises administering a P2X3 antagonist to the mammal, and further comprises administering one or more additional pharmaceutical agents to the mammal.In some embodiments, the method for treating endometriosis, endometriosis-related pain and endometriosis-related symptoms in a mammal in need of treatment comprises administering a compound of formula (I) to the mammal, and further comprises administering one or more additional pharmaceutical agents to the mammal. In some embodiments, the one or more additional pharmaceutical agents are selected from the group consisting of hormonal contraceptives, nonsteroidal anti-inflammatory drugs (NSAIDs), prostaglandin E synthase (PTGES) inhibitors, interleukin-1 receptor associated kinase 4 (IRAK4) inhibitors, prostanoid EP4 receptor antagonists, aldo-keto reductase 1C3 (AKR1C3) inhibitors, and prolactin receptor (PRLR) antagonists. In some embodiments, the additional pharmaceutical agent is a hormonal contraceptive. In some embodiments, the additional pharmaceutical agent is a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the additional pharmaceutical agent is a prostaglandin E synthase (PTGES) inhibitor. In some embodiments, the additional pharmaceutical agent is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. In some embodiments, the additional pharmaceutical agent is a prostanoid EP4 receptor antagonist. In some embodiments, the additional pharmaceutical agent is an aldo-keto reductase 1C3 (AKR1C3) inhibitor. In some embodiments, the additional pharmaceutical agent is a prolactin receptor (PRLR) antagonist.
[0126] Combination therapy also includes administration of the therapeutic agent described above in further combination with other biologically active ingredients and non-drug therapy.Where combination therapy further includes non-drug therapy, non-drug therapy can be administered at any suitable time, as long as beneficial effects from the combination of therapeutic agent and non-drug therapy can be achieved.For example, in suitable cases, even when non-drug therapy is temporarily removed from the administration of therapeutic agent, perhaps for several days or even weeks, beneficial effects can still be achieved.
[0127] The components of the combination are administered to a patient simultaneously or sequentially. It will be appreciated that the components are present in the same pharma- ceutically acceptable carrier and therefore administered simultaneously. Alternatively, the active ingredients are present in separate pharmaceutical carriers that are administered either simultaneously or sequentially, as in conventional oral dosage forms. EXAMPLES
[0128] The examples are provided for illustrative purposes only and are not intended to limit the scope of the claims provided in this disclosure. EXAMPLES
[0129] Syngeneic mouse models of endometriosis The P2X3 receptor antagonist compounds of formula (I) described herein were evaluated in a syngeneic mouse model of endometriosis.
[0130] Part 1: Surgery to implant syngeneic endometrial tissue C57BL / 6 mice (8 weeks old) were anesthetized and then a longitudinal incision was made in the abdomen. The uterus was collected and divided into 5 mm pieces, which were then surgically sutured to the peritoneum of syngeneic recipient animals. Recipient mice were also treated with estradiol, and the resulting lesions were allowed to develop for 11 weeks.
[0131] Part 2: Evaluation of test compounds Baseline measurements were established on day 0 in all transplanted mice by measuring mechanical allodynia using the von Frey pain stimulation procedure according to the protocol described below. On day 1, transplanted mice were injected with saline (intraperitoneally) and mechanical allodynia was measured again using the von Frey filament method (control). On days 4 and 5, transplanted mice were treated with either Compound 1 (30 mg / kg) or positive control (meloxicam, 5 mg / kg) (intraperitoneally). Mechanical allodynia was assessed using the von Frey pain stimulation procedure. All allodynia measurements were performed for 1 hour, followed by treatment. Mice were euthanized on day 6 and evaluated for the presence of endometriotic lesions.
[0132] von Frey pain stimulation procedure Animals were placed in small cages with a mesh or otherwise penetrable bottom. Pain thresholds were assessed with von Frey filaments using a simplified increase-decrease method to determine the mechanical force required to elicit a positive pain response in the animals.
[0133] A von Frey monofilament was applied perpendicular to the abdomen until it was fastened, delivering a constant given force. The force to be tested was progressed by applying filaments of different force, followed by an increasing-decreasing sequence, such that a positive response to the filament indicated the next filament of lower force to be used, whereas a negative response indicated the next filament of higher force to be used. Pain thresholds were measured on the abdomen of each animal. Von Frey monofilaments were applied to the lower to mid-abdomen for 1-2 seconds with an interstimulus interval of at least 10 seconds. Care was taken to avoid the external genitalia and not to stimulate the same spot twice in succession. A clear retraction of the abdomen, immediate licking or scratching at the site of hair application, and escape or jumping trials were considered to be positive responses to abdominal stimulation.
[0134] result The results of the assay are shown in Figure 1A and Figure 1B. The von Frey test is a valid method to evaluate mechanical allodynia in rodents. Increased pressure required to elicit a pain response indicates decreased pain sensation and can help define potential therapeutic agents with analgesic effects. In this example, the von Frey test was used to measure the effect of compound 1 on reducing pain sensation caused by endometriosis in a mouse model. Meloxicam, a therapeutic agent known to reduce pain caused by endometriosis and commonly used in clinical practice, served as a positive control. In the von Frey test, a higher stimulation threshold indicates reduced pain perception. The results presented in Figure 1B reveal that the positive control group treated with meloxicam (5 mg / kg) had increased stimulation thresholds after drug treatment on both days 4 and 5 (p=0.0002 and dp<0.05, respectively), demonstrating that meloxicam reduced pain sensation as expected. Similarly, greater stimulation thresholds were observed for Compound 1 (30 mg / kg) on days 4 and 5 (FIG. 1A), confirming the analgesic effect of Compound 1 as measured by the von Frey assay (p<0.05). Results in FIG. 1A and FIG. 1B are presented as the percentage change (%) from baseline day 0 in the pressure stimulation required to elicit a behavioral response.
Claims
1. In the manufacture of a medicament for the treatment of endometriosis, pain associated with endometriosis and symptoms associated with endometriosis in a mammal in need thereof, 【Chemistry 1】 (In the formula, R 1 is selected from the group consisting of cyano, halogen, methyl and ethyl; R 2 is selected from the group consisting of hydrogen, halogen, methyl and ethyl; R 3 is selected from the group consisting of halogen, methyl and ethyl; R 4 is selected from the group consisting of hydrogen, halogen, methyl, ethyl and methoxy; R 5 and R 6 are independently hydrogen, C 1 ~C 6 Alkyl and Hydroxy C 1 ~C 6 alkyl; or R 5 and R 6 taken together with the nitrogen to which they are both attached form a 5- or 6-membered heterocycloalkyl, where heterocycloalkyl is selected from the group consisting of halogen, hydroxyl, and C 1 ~C 4 optionally substituted with one or more substituents independently selected from the group consisting of alkyl; R 7 and R 8 are independently hydrogen and C 1 ~C 4 selected from the group consisting of alkyl; R 9 is C 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 1 ~C 6 Alkyl-C 3 ~C 6 Cycloalkyl, halo-C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, halo-C 1 ~C 6 Alkoxy and C 1 ~C 6 Alkoxy-C 1 ~C 6 Selected from the group consisting of alkyl R; X is a bond, CH 2 and O. or a pharma- ceutically acceptable salt thereof.
2. R 1 is methyl, R 2 The use according to claim 1 , wherein is hydrogen.
3. R 3 and R 4 The use according to claim 1 , wherein is fluoro.
4. The use according to claim 1 , wherein X is O.
5. The compound may have the structure 【Chemistry 2】 Equivalent to; R 4 The use according to claim 1 , wherein is selected from the group consisting of halogen, methyl and ethyl.
6. R 5 is hydrogen, R 6 is C 1 ~C 6 The use according to claim 1, wherein the aryl group is an alkyl group.
7. R 7 and R 8 is hydrogen and C 1 ~C 6 The use according to claim 1, wherein the aryl group is an alkyl group.
8. The compound may have the structure 【Chemistry 3】 The use according to claim 1, which corresponds to
9. The compound may have the structure 【Chemistry 4-1】 【Chemistry 4-2】 【Chemistry 4-3】 【Chemistry 4-4】 【Chemistry 4-5】 The use according to claim 1, which corresponds to
10. The compound may have the structure 【Chemistry 5】 The use according to claim 1, which corresponds to
11. The compound may have the structure 【Chemistry 6】 The use according to claim 1, which corresponds to
12. The compound may have the structure 【Chemistry 7】 The use according to claim 1, which corresponds to
13. The compound may have the structure 【Chemistry 8】 The use according to claim 1, which corresponds to
14. 2. The use of claim 1 for treating symptoms associated with endometriosis in a mammal in need thereof, wherein the symptoms associated with endometriosis are selected from dysmenorrhea, dyspareunia, difficulty urinating and difficulty defecation.
15. The use according to any one of claims 1 to 14, further comprising the use of a second therapeutic agent.
16. 16. The use of claim 15, wherein the second therapeutic agent is selected from hormonal contraceptives, nonsteroidal anti-inflammatory drugs (NSAIDs), prostaglandin E synthase (PTGES) inhibitors, interleukin-1 receptor associated kinase 4 (IRAK4) inhibitors, prostanoid EP4 receptor antagonists, aldo-keto reductase 1C3 (AKR1C3) inhibitors and prolactin receptor (PRLR) antagonists.
Citation Information
Patent Citations
Applications of P2X3 acceptor conditioning agent benzimidazole compound in preparation of medicines used for treating respiratory diseases
CN108904507A
Benzimidazole compounds and their use
JP2013511517A
Imidazopyridine compounds and their use
JP2016506935A
1,3-thiazol-2-yl substituted benzamide
JP2017537122A
Selective P2X3 modulators
US10111883B1
